Literature DB >> 16954236

Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test.

Dennis van Hamont1, Maaike A P C van Ham, Judith M J E Bakkers, Leon F A G Massuger, Willem J G Melchers.   

Abstract

The need for accurate genotyping of human papillomavirus (HPV) infections is becoming increasingly important, since (i) the oncogenic potential among the high-risk HPV genotypes varies in the pathogenesis of cervical cancer, (ii) monitoring multivalent HPV vaccines is essential to investigate the efficiency of the vaccines, and (iii) genotyping is crucial in epidemiologic studies evaluating HPV infections worldwide. Various genotyping assays have been developed to meet this demand. Comparison of different studies that use various HPV genotyping tests is possible only after a performance assessment of the different assays. In the present study, the SPF(10) LiPA version 1 and the recently launched Roche Linear Array HPV genotyping assays are compared. A total of 573 liquid-based cytology samples were tested for the presence of HPV by a DNA enzyme immunoassay; 210 were found to be positive for HPV DNA and were evaluated using both genotyping assays (163 with normal cytology, 22 with atypical squamous cells of undetermined significance, 20 with mild/moderate dysplasia, and 5 with severe dysplasia). Comparison analysis was limited to the HPV genotype probes common to both assays. Of the 160 samples used for comparison analysis, 129 (80.6%) showed absolute agreement between the assays (concordant), 18 (11.2%) showed correspondence for some but not all genotypes detected on both strips (compatible), and the remaining 13 (8.2%) samples did not show any similarity between the tests (discordant). The overall intertest comparison agreement for all individually detectable genotypes was considered very good (kappa value, 0.79). The genotyping assays were therefore highly comparable and reproducible.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16954236      PMCID: PMC1594724          DOI: 10.1128/JCM.00517-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

2.  Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening.

Authors:  K R Lee; R Ashfaq; G G Birdsong; M E Corkill; K M McIntosh; S L Inhorn
Journal:  Obstet Gynecol       Date:  1997-08       Impact factor: 7.661

3.  A study of the impact of adding HPV types to cervical cancer screening and triage tests.

Authors:  Mark Schiffman; Michelle J Khan; Diane Solomon; Rolando Herrero; Sholom Wacholder; Allan Hildesheim; Ana Cecilia Rodriguez; Maria C Bratti; Cosette M Wheeler; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

4.  Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus.

Authors:  B Kleter; L J van Doorn; L Schrauwen; A Molijn; S Sastrowijoto; J ter Schegget; J Lindeman; B ter Harmsel; M Burger; W Quint
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

5.  Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing.

Authors:  M E Sherman; M H Schiffman; A T Lorincz; R Herrero; M L Hutchinson; C Bratti; D Zahniser; J Morales; A Hildesheim; K Helgesen; D Kelly; M Alfaro; F Mena; I Balmaceda; L Mango; M Greenberg
Journal:  Cancer       Date:  1997-04-25       Impact factor: 6.860

Review 6.  The epidemiology of human papillomavirus infections.

Authors:  Janet G Baseman; Laura A Koutsky
Journal:  J Clin Virol       Date:  2005-03       Impact factor: 3.168

7.  Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses.

Authors:  B Kleter; L J van Doorn; J ter Schegget; L Schrauwen; K van Krimpen; M Burger; B ter Harmsel; W Quint
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

8.  The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months.

Authors:  A J Remmink; J M Walboomers; T J Helmerhorst; F J Voorhorst; L Rozendaal; E K Risse; C J Meijer; P Kenemans
Journal:  Int J Cancer       Date:  1995-05-04       Impact factor: 7.396

9.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

10.  Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia.

Authors:  J Cuzick; G Terry; L Ho; T Hollingworth; M Anderson
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

View more
  56 in total

1.  Comparison of PapType to Digene Hybrid Capture 2, Roche linear array, and Amplicor for detection of high-risk human papillomavirus genotypes in women with previous abnormal pap smears.

Authors:  Sepehr N Tabrizi; Matthew P Stevens; Zaheer A Khan; Conan Chow; Martin A Devitt; Suzanne M Garland
Journal:  J Clin Microbiol       Date:  2012-05-30       Impact factor: 5.948

2.  Human papillomavirus quantification in urine and cervical samples by using the Mx4000 and LightCycler general real-time PCR systems.

Authors:  Christopher Payan; Alexandra Ducancelle; Mohamed H Aboubaker; Julien Caer; Malena Tapia; Amelie Chauvin; Damien Peyronnet; Elodie Le Hen; Zohra Arab; Marie-Christine Legrand; Adissa Tran; Edith Postec; Françoise Tourmen; Martine Avenel; Chantal Malbois; Marie-Anne De Brux; Philippe Descamps; Francoise Lunel
Journal:  J Clin Microbiol       Date:  2007-01-17       Impact factor: 5.948

3.  Evaluation of different techniques for identification of human papillomavirus types of low prevalence.

Authors:  Ivan Sabol; Martina Salakova; Jana Smahelova; Michal Pawlita; Markus Schmitt; Nina Milutin Gasperov; Magdalena Grce; Ruth Tachezy
Journal:  J Clin Microbiol       Date:  2008-03-05       Impact factor: 5.948

4.  Effect of ThinPrep preparation on human papillomavirus detection and genotyping in rectal samples by PCR.

Authors:  Sepehr N Tabrizi; Matthew P Stevens; Marina T van Leeuwen; Claire M Vajdic; Leon P Botes; Gabriele Medley; Richard Hillman; Andrew Grulich; Suzanne M Garland
Journal:  J Clin Microbiol       Date:  2008-11-12       Impact factor: 5.948

5.  Validation of an automated detection platform for use with the roche linear array human papillomavirus genotyping test.

Authors:  Matthew P Stevens; Suzanne M Garland; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2008-09-10       Impact factor: 5.948

6.  Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes.

Authors:  C Estrade; P-A Menoud; D Nardelli-Haefliger; R Sahli
Journal:  J Clin Microbiol       Date:  2011-08-10       Impact factor: 5.948

7.  Comparison of the INNO-LiPA and PapType assays for detection of human papillomavirus in archival vulva dysplasia and/or neoplasia tissue biopsy specimens.

Authors:  Sarah E Tan; Suzanne M Garland; Alice R Rumbold; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2011-09-21       Impact factor: 5.948

8.  Coexisting high-grade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: independent lesions due to different HPV types occurring in immunocompromised patients.

Authors:  Kruti P Maniar; Brigitte M Ronnett; Russell Vang; Anna Yemelyanova
Journal:  Am J Surg Pathol       Date:  2013-01       Impact factor: 6.394

9.  Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results.

Authors:  Matthew P Stevens; Suzanne M Garland; Elice Rudland; Jeffrey Tan; Michael A Quinn; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

10.  Patients with usual vulvar intraepithelial neoplasia-related vulvar cancer have an increased risk of cervical abnormalities.

Authors:  R P de Bie; H P van de Nieuwenhof; R L M Bekkers; W J G Melchers; A G Siebers; J Bulten; L F A G Massuger; J A de Hullu
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.